Tvardi Therapeutics, Inc. (TVRD) News
Follow Tvardi Therapeutics, Inc. (TVRD) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 11 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Tvardi Therapeutics, Inc. (TVRD) Reports New Preclinical UC Data Supporting STAT3 Inhibitors
Tvardi published preclinical data showing its oral STAT3 inhibitors reached high colon exposure and modulated disease biology in UC models, including preventing adenocarcinomas in an AOM-DSS mouse model, supporting advan
NEWS | Sep 24, 2026, 12:03 PM UTC
L
New Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC)
In a preclinical chronic colitis model, Tvardi’s oral small molecule accumulated in the colon at approximately 8-fold higher concentrations than in plasma, at pharmacologically relevant levels, and modulated STAT3-driven
NEWS | Sep 24, 2026, 12:03 PM UTC
L
TVRD - New Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC)
TVRD - New Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC)
NEWS | Sep 24, 2026, 12:01 PM UTC
L
LUCID CAPITAL MARKETS sets TVARD $14 price target
TradingView News (via Benzinga) reports LUCID CAPITAL MARKETS announced a $14.00-per-share price target for TVARD.
EQUITY | Sep 08, 2026, 12:20 PM UTC
L
Tvardi Therapeutics to Participate in Upcoming Investor Events
Tvardi Therapeutics to Participate in Upcoming Investor Events
EQUITY | Aug 26, 2026, 12:07 PM UTC
L
TVRD - Tvardi Therapeutics to Participate in Upcoming Investor Events
TVRD - Tvardi Therapeutics to Participate in Upcoming Investor Events
EQUITY | Aug 26, 2026, 12:00 PM UTC
L
Tvardi Therapeutics reports Q2 2026 results, issues business update
Tvardi Therapeutics (TVRD) announces its second quarter 2026 results and provides a business update, according to TradeXchange Newsdesk.
EARNINGS | Aug 14, 2026, 11:00 AM UTC
L
Tvardi Therapeutics Hosts Webinar
Tvardi Therapeutics is hosting a webinar on TTI-109 in ulcerative colitis
EQUITY | Aug 12, 2026, 12:00 PM UTC
M
Tvardi Therapeutics Targets Ulcerative Colitis
Tvardi Therapeutics selects initial indication
EQUITY | Jul 30, 2026, 11:30 AM UTC
H
Why Universe Pharmaceuticals Shares Are Trading Higher By Around 228%; Here Are 20 Stocks Moving Premarket
Shares of Universe Pharmaceuticals Inc (NASDAQ: UPC ) rose sharply in pre-market trading after the company announced it will acquire Best Praise International for $10.75 million. Universe Pharmaceuticals shares jumped 22
RATES | Jun 29, 2026, 11:03 AM UTC
M
12 Health Care Stocks Move
Gainers Universe Pharmaceuticals (NASDAQ: UPC ) stock moved upwards by 168.2% to $7.94 during Friday's after-market session. The market value of their outstanding shares is at $1.8 million. Tvardi Therapeutics (NASDAQ: T
EQUITY | Jun 26, 2026, 11:20 PM UTC